RT Journal Article
SR Electronic
T1 Community-Based Phenotypic Study of Safety, Tolerability, Reactogenicity and Immunogenicity of Emergency-Use-Authorized Vaccines Against COVID-19 and Viral Shedding Potential of Post-Vaccination Infections: Protocol for an Ambispective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.28.21256779
DO 10.1101/2021.06.28.21256779
A1 Gabashvili, Irene S.
YR 2021
UL http://medrxiv.org/content/early/2021/07/21/2021.06.28.21256779.abstract
AB The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to a global pandemic that disrupted and impacted lives in unprecedented ways. Within less than a year after the beginning of the COVID-19 pandemic, vaccines developed by several research teams were emergency-use authorized and made their way to distribution sites across the US and other countries. COVID-19 vaccines were tested in clinical trials with thousands of participants before authorization, and were administered to over a billion people across the globe in the following 6 months. Post-authorization safety monitoring was performed using pre-existing systems (such as the World Health Organization’s platform VigiBase or US Vaccine Adverse Event Reporting System, VAERS) and newly developed post-vaccination health checkers (such as V-safe in the US). Vaccinated individuals were also posting their experiences on multiple social media groups created on Facebook, Reddit, Telegram and other platforms, but the groups were often removed as “proliferating false claims”. These forms of reporting are susceptible to biases and misclassifications and do not reach all vaccinated individuals, raising questions about risks of exacerbating health inequalities as well as security and privacy vulnerabilities.The objective of this paper is to present the protocol for a community-based participatory research approach enabling long-term monitoring of health effects, strengthening community participation via transparent messaging and support, and addressing challenges of transitioning to a new normal.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04832932Funding StatementThe author received no financial support for the research, authorship, and/or publication of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was submitted to and approved by MEBO Research Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data collected in this study will be made available anonymized to other academic researchers. For more details see https://aurametrix.com/Studies/NCT04832932.html